Multiplex Assay Kit for Cyclophilin A (CYPA) ,etc. by FLIA (Flow Luminescence Immunoassay) 
PPIA; CyP-A; CYPH; Peptidylprolyl Isomerase A; Peptidyl-Prolyl Isomerase A; Peptidyl-prolyl cis-trans isomerase A; Cyclosporin A-binding protein
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 427.00 US$ 443.00 US$ 468.00 US$ 501.00 US$ 534.00 US$ 583.00 US$ 657.00 US$ 821.00
- Quantity
Overview
Properties
- Product No.LMA979Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryTumor immunityInfection immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Cyclophilin A (CYPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Cyclophilin A (CYPA) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 90-101 | 97 |
| EDTA plasma(n=5) | 82-96 | 90 |
| heparin plasma(n=5) | 84-102 | 94 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cyclophilin A (CYPA) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cyclophilin A (CYPA) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cyclophilin A (CYPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 87-96% | 78-91% | 78-88% | 95-105% |
| EDTA plasma(n=5) | 91-101% | 97-105% | 81-101% | 96-104% |
| heparin plasma(n=5) | 80-103% | 97-104% | 84-92% | 85-92% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:CYPA) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formationPubMed: 19758589
- Cyclophilin-A: a novel biomarker for untreated male essential hypertensionPubmed: 24164594
- Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular diseasePubmed:24502618
- Decrease in Plasma Cyclophilin A Concentration at 1 Month after Myocardial Infarction Predicts Better Left Ventricular Performance and Synchronicity at 6 Months: A Pilot Study in Patients with ST Elevation Myocardial InfarctionPubmed:25552928
- Cyclophilin A in Ruptured Intracranial AneurysmPubMed: 26426668
- PPIA rs6850: A> G single-nucleotide polymorphism is associated with raised plasma cyclophilin A levels in patients with coronary artery diseasePubMed: 26702934
- Urinary Cyclophilin A as a New Marker for Diabetic Nephropathy: A Cross-Sectional Analysis of Diabetes MellitusPubMed: 26496315
- Cyclophilin A modulates bone marrow-derived CD117(+) cells and enhances ischemia-induced angiogenesisvia the SDF-1/CXCR4 axis.Pubmed:27057951
- Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitorpubmed:27823952
- Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus.pubmed:27809851
- Metformin attenuates effects of cyclophilin A on macrophages, reduces lipid uptake and secretion of cytokines by repressing decreased AMPK activityPubmed:29382697
- Cyclophilin a increases CD68 cell infiltration in rat experimental periodontitisPubmed:29318411
- Cyclophilin A and CD147 associate with progression of diabetic nephropathyPubmed: 30572748
- Association of cyclophilin A level and pulse pressure in predicting recurrence of cerebral infarctionPubmed: 31670477
- Cyclophilin A/EMMPRIN Axis Is Involved in Pro-Fibrotic Processes Associated with Thoracic Aortic Aneurysm of Marfan Syndrome PatientsPubmed: 31936351
- APPENDIX A: Relationship between cyclophilin A levels and matrix metalloproteinase-9 activity in cerebrospinal fluid of cognitively normal apolipoprotein E4 carriers …Pubmed: 24030206
- Urinary podocalyxin and cyclophilin A: markers for early detection of type 2 diabetic nephropathy
- Evaluation of the Therapeutic Effects of Protocatechuic Aldehyde in Diabetic Nephropathy34437430
- Proteomic analysis reveals USP7 as a novel regulator of palmitic acid-induced hepatocellular carcinoma cell deathPubmed:35732625